Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
What dose contraints do use for the pulmonary artery and vein when treating with a lung lesion with SBRT?
Related Questions
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
Would you offer empiric lung SBRT for two growing FDG-avid lung lesions in a patient with severe COPD on oxygen?
Can palliative radiation be used to treat recurrent malignant pleural effusion in NSCLC?
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
Would you treat a patient with an N2 ipsilateral recurrence following re-resection of bronchial stump recurrence?
What is the recommendation for persistent PET uptake and elevated catecholamines at 4 months following subtotal resection and adjuvant radiation for a thoracic secretory paraganglioma?
What radiation treatment volume would you include in chemoradiation given for perihilar lymph node recurrence after surgical resection and mediastinal lymph node dissection for NSCLC?
In resected N2 NSCLC, what nodal pathologic characteristics prompt you to recommend PORT?
In a patient who underwent cryoablation for early NSCLC, is there a role for giving preemptive further local therapy?
Is there a role for the addition of radiation to preoperative chemoimmunotherapy in NSCLC with limited N2 disease planned for surgery?
